InvestorNewsBreaks - Silo Pharma Inc. (NASDAQ: SILO) Expects SPC-15 PTSD Study Results Within 90 Days 

Stock Information for Silo Pharma Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Silo Pharma Inc.

Silo Pharma Partners with Allucent to Support Planned FDA Investigational New Drug Application for SPC-15 as a Therapeutic for PTSD
Silo Pharma Selects Alphaledger's T12 Fund for Tokenized Real-World Asset Investments on Solana Blockchain
Silo Pharma Issues Update on Milestone Achievements in PTSD Drug Development and New Digital Assets Treasury Program
Silo Pharma Expands Crypto Treasury with First Strategic Bitcoin Purchase Reinforcing Company's Commitment to Multi-Chain Growth
Silo Pharma Acquires ResearchCoin (RSC) Crypto Tokens in Support of Decentralized Science (DeSci)
Silo Pharma Announces Closing of $2.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Silo Pharma Announces $2.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
Silo Pharma Updates Strategic Agreement with Fireblocks to Secure Crypto Treasury Management

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.